Beam Therapeutics Inc. (BEAM): Share Price, Stock Analysis, Annual Report | Value Research Get Beam Therapeutics Inc. (BEAM)'s stock analysis, price valuation, corporate actions, and financials from India's independent mutual fund research house.
info-circle
company-logo

Click to see a quick summary and important updates about this stock!Dismiss

  • Healthcare
  • Biotechnology & Pharma Research

Beam Therapeutics Inc. (BEAM)

NASDAQ: BEAM

  • Market Capitalisation info

    $4,947 Mln


  • 12 Month Earnings info

    $-234 Mln

  • Price to Earnings info

    --

$59.69

As on 17-Aug-2022 13:26 EDT

up-down-arrow $-3.87-6.10%

  • Prev Close info

    $63.56

  • Day's Openinfo

    $61.74

  • Today's Highinfo

    $62.61

  • Today's Lowinfo

    $59.52

  • Today's Volumeinfo

    711,065

Please wait...

Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Beam Therapeutics (BEAM)
-25.10 3.59 83.42 -41.45 -- -- --
S&P BSE Sensex
3.44 12.09 13.75 8.42 17.29 13.66 13.06
S&P Small-Cap 600
-8.42 12.89 8.31 -4.42 11.76 8.97 10.87
As on 17-Aug-2022
2021
Beam Therapeutics (BEAM)
-2.39
S&P Small-Cap 600
25.27
S&P BSE Sensex
21.99

Valuation

Stock
Peer Median

Growth & Efficiency

Stock
Peer Median

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other Details

        CEO & Director

        Mr. John M. Evans M.B.A.

        Pres & Chief Scientific Officer

        Dr. Giuseppe Ciaramella Ph.D.

        Headquarters

        Cambridge, MA
        Edit edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap info

          $4,946.63 Mln

        • Revenue (TTM) info

          $76.92 Mln

        • Earnings (TTM) info

          $-233.99 Mln

        • Cash info

          $1,166.12 Mln

        • Total Debt info

          $173.50 Mln

        • Insider's Holding

          1.94%

        • Liquidity info

          Low

        • 52 Week range info

          $27.77 - 116.91

        • Shares outstanding info

          70,354,600

        • 10 Years Aggregate:

          CFO: $544.98 Mln

          EBITDA: $-618.89 Mln

          Net Profit: $-21.92 Mln

        About The Company

        • Business

          Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States.

        • IPO Date

          06-Feb-2020

        • CEO & Director

          Mr. John M. Evans M.B.A.

        • Pres & Chief Scientific Officer

          Dr. Giuseppe Ciaramella Ph.D.

        • Listing info

          NASDAQ: BEAM

        • Country

          United States

        • Headquarters info

          Cambridge, MA

        • Website info

          https://www.beamtx.com